BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 226 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q1 2021. The put-call ratio across all filers is 1.62 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $4,831,000 | -4.9% | 31,959 | -8.3% | 0.06% | 0.0% |
| Q2 2022 | $5,080,000 | +22.0% | 34,866 | -0.7% | 0.06% | +47.7% |
| Q1 2022 | $4,165,000 | -39.6% | 35,127 | -29.8% | 0.04% | -37.1% |
| Q4 2021 | $6,892,000 | -32.7% | 50,011 | -32.2% | 0.07% | -31.4% |
| Q3 2021 | $10,248,000 | +41.1% | 73,777 | -1.4% | 0.10% | +41.7% |
| Q2 2021 | $7,265,000 | +36.2% | 74,840 | -4.1% | 0.07% | +28.6% |
| Q1 2021 | $5,336,000 | +43.2% | 78,063 | +79.6% | 0.06% | +33.3% |
| Q4 2020 | $3,725,000 | +29.1% | 43,460 | -2.1% | 0.04% | +7.7% |
| Q3 2020 | $2,885,000 | -24.1% | 44,372 | -14.6% | 0.04% | -27.8% |
| Q2 2020 | $3,799,000 | +145.9% | 51,964 | +14.5% | 0.05% | +107.7% |
| Q1 2020 | $1,545,000 | -40.1% | 45,388 | -4.2% | 0.03% | -21.2% |
| Q4 2019 | $2,580,000 | – | 47,384 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 2,111,111 | $144,294,000 | 54.16% |
| Knoll Capital Management, LLC | 856,844 | $58,565,000 | 38.16% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,123,271 | $145,126,000 | 21.73% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 860,261 | $58,799,000 | 6.01% |
| ARS Investment Partners, LLC | 561,442 | $38,375,000 | 4.46% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $12,057,000 | 3.19% |
| Eventide Asset Management | 2,015,000 | $137,725,000 | 2.04% |
| Avidity Partners Management LP | 1,049,800 | $71,754,000 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,089 | $3,424,000 | 1.87% |
| Nicholas Investment Partners, LP | 375,654 | $25,676,000 | 1.79% |